ArticleScience (New York, N.Y.)2024
An antibiotic preorganized for ribosomal binding overcomes antimicrobial resistance.
Open access · greenAbstract read
In one paragraph
Article in Science (New York, N.Y.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
15.9field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 68 citations in OpenAlex.
- Predicting resistance evolution to guide antibiotic development.Nature reviews. Microbiology · 2026Review
- Engineering "Yin-Yang" Ag/AgCl-Polymer Nanotherapeutic for Tunable Silver Ion Release With Improved In Vivo Biocompatibility and Antimicrobial Potency.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Sparsomycin inhibits translation through a conserved mechanism across all domains of life.Nucleic acids research · 2026Article
- Current Recommendations, Antibiotic Resistance, and Emerging Treatments for Gram-Positive Ocular Infections in the United States.Antibiotics (Basel, Switzerland) · 2026Review
- Quantum Chemical Insights into Antibiotic Structure-Activity Relationships and Mechanisms of Action: A Review.Molecules (Basel, Switzerland) · 2026Review
- Genetic and pharmacological inactivation of peptidoglycan remodeling increases antibiotic susceptibility of vancomycin-resistant Enterococcus faecium.Nature communications · 2026Article
- A multi-stage computational pipeline andRSC advances · 2026Article
- Genetic and pharmacological inactivation of peptidoglycan remodeling increases antibiotic susceptibility of vancomycin-resistantbioRxiv : the preprint server for biology · 2026Article
- Emerging synthetic biology-assisted technologies for overcoming antibiotic resistance: CRISPR-Cas, bacteriophage, microbiome, and metabolic engineering-based solutions.Journal of microbiology (Seoul, Korea) · 2026Review
- A target-guided drug repurposing strategy for antibacterial discovery.BMC microbiology · 2026Article
- Enantioconvergent radical addition of racemic alkyl halides to access vicinal stereocentres.Nature chemistry · 2026Article
- Quercetin Enhances the Antibacterial Activity of Polymyxin E Against MCR-1-Positive Bacteria by Inhibiting the Biological Functions of the Cell Membrane.Animals : an open access journal from MDPI · 2025Article
- Omadacycline Pharmacokinetics: Characteristics, Contributing Factors, and Clinical Significance.Drugs in R&D · 2025Review
- Hybrid Antibiotics Targeting the Bacterial Ribosome.ACS central science · 2025Article
- Beyond the Resistome: Molecular Insights, Emerging Therapies, and Environmental Drivers of Antibiotic Resistance.Antibiotics (Basel, Switzerland) · 2025Review
- Article
- Basis for selective drug evasion of an aminoglycoside-resistance ribosomal RNA modification.Nature communications · 2025Article
- Anchored atomic Ru-ONature communications · 2025Article
- Non-Amphiphilic Antimicrobial Polymers.Angewandte Chemie (International ed. in English) · 2025Article
- Global health perspectives on antibacterial drug discovery and the preclinical pipeline.Nature reviews. Microbiology · 2025Review
Corrections and comments
- Commented on by
Authors and funding
15 authors at 2 institutions in 1 country.
Kelvin J Y WuDepartment of Chemistry and Chemical Biology, Harvard University, Cambridge, MA 02138, USA.ORCID 0000-0002-5561-6369
Ben I C TrescoDepartment of Chemistry and Chemical Biology, Harvard University, Cambridge, MA 02138, USA.
Antonio RamkissoonDepartment of Chemistry and Chemical Biology, Harvard University, Cambridge, MA 02138, USA.
Elena V AleksandrovaDepartment of Biological Sciences, University of Illinois at Chicago, Chicago, IL 60607, USA.ORCID 0000-0002-1808-5319
Egor A SyroeginDepartment of Biological Sciences, University of Illinois at Chicago, Chicago, IL 60607, USA.ORCID 0000-0003-2753-3950
Dominic N Y SeeDepartment of Chemistry and Chemical Biology, Harvard University, Cambridge, MA 02138, USA.ORCID 0009-0006-0466-9117
Priscilla LiowDepartment of Chemistry and Chemical Biology, Harvard University, Cambridge, MA 02138, USA.
Georgia A DittemoreDepartment of Chemistry and Chemical Biology, Harvard University, Cambridge, MA 02138, USA.ORCID 0000-0003-4749-977X
Meiyi YuDepartment of Chemistry and Chemical Biology, Harvard University, Cambridge, MA 02138, USA.
Giambattista TestolinDepartment of Chemistry and Chemical Biology, Harvard University, Cambridge, MA 02138, USA.ORCID 0000-0003-0080-0692
Matthew J MitcheltreeDepartment of Chemistry and Chemical Biology, Harvard University, Cambridge, MA 02138, USA.ORCID 0000-0003-3774-628X
Richard Y LiuDepartment of Chemistry and Chemical Biology, Harvard University, Cambridge, MA 02138, USA.ORCID 0000-0003-0951-6487
Maxim S SvetlovDepartment of Pharmaceutical Sciences, University of Illinois at Chicago, Chicago, IL 60607, USA.ORCID 0000-0003-1459-5685
Yury S PolikanovDepartment of Biological Sciences, University of Illinois at Chicago, Chicago, IL 60607, USA.ORCID 0000-0002-5064-0327
Andrew G MyersDepartment of Chemistry and Chemical Biology, Harvard University, Cambridge, MA 02138, USA.ORCID 0000-0001-9602-6915
Harvard University · USUniversity of Illinois Chicago · US
Funding
User Training and OutreachP30GM124165 · NIGMS · CORNELL UNIVERSITY · PI Nozomi Ando, J Christopher Fromme · 2018 to 2026
$34.2MDiscovery through chemical synthesis of antibiotics effective against modern bacterial pathogensR01AI168228 · NIAID · HARVARD UNIVERSITY · PI ANDREW G MYERS · 2022 to 2026
$3.8MHarvard Chemical Biology PhD ProgramT32GM139775 · NIGMS · HARVARD UNIVERSITY · PI Emily Patricia Balskus, PHILIP A COLE · 2022 to 2026
$2.6MPixel Array Detector for Macromolecular CrystallographyS10OD021527 · OD · CORNELL UNIVERSITY · PI EALICK, STEVEN E · 2016 to 2016
$2.0MMolecular mechanisms of action of ribosome-targeting antibiotics.R01GM132302 · NIGMS · UNIVERSITY OF ILLINOIS AT CHICAGO · PI POLIKANOV, YURY · 2019 to 2022
$1.3MStructural basis of Erm-mediated macrolide resistanceR21AI137584 · NIAID · UNIVERSITY OF ILLINOIS AT CHICAGO · PI MANKIN, ALEXANDER S, POLIKANOV, YURY · 2018 to 2019
$440kStructural basis of Cfr-mediated resistance to antibiotics targeting the bacterial ribosomeR21AI163466 · NIAID · UNIVERSITY OF ILLINOIS AT CHICAGO · PI POLIKANOV, YURY · 2021 to 2022
$426kNIAID NIH HHS R01 AI168228NIAID NIH HHS R21 AI137584NIAID NIH HHS R21 AI163466NIGMS NIH HHS P30 GM124165NIGMS NIH HHS R01 GM132302NIGMS NIH HHS T32 GM139775NIH HHS S10 OD021527
Abstract
We report the design conception, chemical synthesis, and microbiological evaluation of the bridged macrobicyclic antibiotic cresomycin (CRM), which overcomes evolutionarily diverse forms of antimicrobial resistance that render modern antibiotics ineffective. CRM exhibits in vitro and in vivo efficacy against both Gram-positive and Gram-negative bacteria, including multidrug-resistant strains of
Indexed as
Anti-Bacterial AgentsBridged-Ring CompoundsDrug Resistance, Multiple, BacterialLincosamidesOxepinsAnimalsDrug DesignErythromycinEscherichia coliMiceMicrobial Sensitivity TestsPseudomonas aeruginosaRibosomesStaphylococcus aureusAnti-Bacterial AgentsBridged-Ring CompoundscresomycinErythromycinLincosamidesOxepins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.